Targets › NR3C1
53 programs from 47 companies in 222 trials: 77 Phase 4, 67 Phase 2, 44 Phase 3, 34 Phase 1; Immunology, Other, Oncology; next expected readout Nov 2026.
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. (UniProt, P04150)
Open in Phaseline: the race on NR3C1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Wake Forest University Health Sciences | Triamcinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Central Centrifugal Cicatricial Alopecia (CCCA) | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| University of Calgary | CBD 100 mg OD Interleukin-23 inhibitor | CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1 | Phase 4 | Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope … | Dec 2026 |
| The University of Hong Kong | Triamcinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Patella Fracture | Dec 2026 |
| Diakonhjemmet Hospital | Triamcinolone acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Osteoarthritis Thumb; Carpal Tunnel Syndrome | Feb 2027 |
| Christian Candrian | Dexamethasone Sodium Phosphate Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Total Knee Replacement | Apr 2027 |
| AstraZeneca | Budesonide (PT027) Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Chronic Obstructive Pulmonary Disease; Asthma; Functional Dyspepsia; IgA Nephropathy … | May 2027 |
| Hospital JP Garrahan | ESHAP Combination chemotherapy: Etoposide (topoisomerase II inhibitor), Methylprednisolone (cort | TOP2B, NR3C1 | Phase 4 | Pediatric Hodgkin's Disease | Oct 2027 |
| McMaster University | Beclomethasone Dipropionate Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Asthma | Jun 2028 |
| Santhera Pharmaceuticals | vamorolone Glucocorticoid receptor agonist; Mineralocorticoid receptor antagonist | NR3C1, NR3C2 | Phase 4 | Duchenne Muscular Dystrophy | Sep 2028 |
| Alimera Sciences | Fluocinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Diabetic Macular Edema; Non-infectious Uveitis Affecting the Posterior Segment of the Eye; Diabetic Macular Edema (DME); Radiation Retinopathy | Oct 2028 |
| Igor Wilderman. MD | Triamcinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Back Pain Lower Back | Dec 2029 |
| Viatris | Fluticasone Propionate Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Allergic Rhinitis Due to Allergens | – |
| Centre hospitalier de l'Université de Montréal (CHUM) | Triamcinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 4 | Primary Gonarthrosis | – |
| Pacira Pharmaceuticals | Triamcinolone Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Glenohumeral Osteoarthritis; Pain; Osteoarthritis, Knee; Osteoarthritis of Knee … | Dec 2026 |
| Corcept Therapeutics | relacorilant Glucocorticoid receptor antagonist | NR3C1 | Phase 3 | Ovarian Neoplasm; Cushing Syndrome; Ovarian Cancer; Adenocarcinoma … | Dec 2026 |
| Tiohundra | Hydrocortisone Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial; Pituitary Adenoma; Adrenal Insufficiency; Shock … | Jan 2027 |
| Leiden University Medical Center | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 3 | Female Contraception | Jun 2027 |
| YiLin | Methylprednisolone sodium succinate Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Large Infarct Core | Sep 2027 |
| Tang-Du Hospital | methylprednisolone sodium succinate Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Acute Ischemic Stroke; Ischemia Stroke | Dec 2027 |
| Optinose US | Fluticasone Propionate (OPN-375) Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Chronic Rhinosinusitis Without Nasal Polyps; Allergic Rhinitis; Healthy; Chronic Cough … | Mar 2028 |
| Sint Maartenskliniek | Methylprednisolone Acetate Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Hand Osteoarthritis | Apr 2028 |
| Jeremy Keenan, MD, MPH | Dexamethasone sodium phosphate Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Acanthamoeba Keratitis | Jul 2029 |
| Wan-Jin Chen | Methylprednisolone sodium succinate Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Acute Ischemic Stroke | Jun 2030 |
| Teva Branded Pharmaceutical Products R&D | Fluticasone Propionate Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Asthma | – |
| Laboratorios Sophia S.A de C.V. | Moxifloxacin (PRO-232) Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor | GYRB, NR3C1 | Phase 3 | Cataract Extraction | – |
| VA Office of Research and Development | Triamcinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Osteoarthritis of the Knee | – |
| Christiaan Vinkers | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 2 | Treatment-resistant PTSD | Nov 2026 |
| Daniel Raper, MBBS | Methylprednisolone sodium succinate Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Headaches Associated With Subarachnoid Hemorrhage (SAH) | Jan 2027 |
| Chelsea and Westminster NHS Foundation Trust | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 2 | Labor, Induced | Mar 2027 |
| Memorial Sloan Kettering Cancer Center | Triamcinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Glioblastoma | Jul 2027 |
| University of Palermo | Clobetasol Propionate Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Oral Lichen Planus | Oct 2027 |
| Memorial Sloan Kettering Cancer Center | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 2 | Metastatic Breast Cancer | Oct 2027 |
| Corcept Therapeutics | Dazucorilant (CORT113176) Glucocorticoid receptor antagonist | NR3C1 | Phase 2 | Amyotrophic Lateral Sclerosis | Nov 2027 |
| Université du Québec à Trois-Rivières | Triamcinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Trapeziometacarpal Osteoarthritis | Dec 2027 |
| Memorial Sloan Kettering Cancer Center | Mometasone Furoate Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Breast Cancer | Oct 2028 |
| University of Alabama at Birmingham | Beclomethasone Dipropionate Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Asthma | Dec 2028 |
| Oticara Australia | Betamethasone Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Chronic Rhinosinusitis (Diagnosis); Hemiplegia; Myofascial Pain Dysfunction Syndrome; Anaphylactic Reaction … | – |
| Malmö University | Clobetasol Propionate Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Oral Lichen Planus | – |
| Post Graduate Institute of Medical Education and Research, Chandigarh | Deflazacort Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Allergic Bronchopulmonary Aspergillosis | – |
| University of Chicago | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 2 | Breast Cancer | – |
| Corcept Therapeutics | Miricorilant Glucocorticoid receptor modulator | NR3C1 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | – |
| Universitas Padjadjaran | Triamcinolone Acetonide Glucocorticoid receptor agonist | NR3C1 | Phase 2 | Keloid Scars | – |
| The Methodist Hospital Research Institute | Dexamethasone Sodium Phosphate Glucocorticoid receptor agonist | NR3C1 | Phase 1 | Ureteral Stent-Related Symptom | Dec 2026 |
| Eupraxia Pharmaceuticals | EP-104GI Extended-release fluticasone propionate for gastrointestinal administration | NR3C1 | Phase 1 | Eosinophilic Esophagitis | Dec 2026 |
| Corcept Therapeutics | Nenocorilant Glucocorticoid receptor antagonist | NR3C1 | Phase 1 | Neoplasms | Jan 2027 |
| M.D. Anderson Cancer Center | CB-NK-TGF-betaR2-/NR3C1- Cord blood-derived engineered natural killer cells with deleted TGF-betaR2 and NR3C1 (gluc | TGFBR2, NR3C1 | Phase 1 | Recurrent Gliosarcoma | Jan 2027 |
| Venkatesh Sampath | Ciclesonide Glucocorticoid receptor agonist | NR3C1 | Phase 1 | Bronchopulmonary Dysplasia | May 2027 |
| Montefiore Medical Center | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 1 | Cervical Preparation | Jun 2027 |
| M.D. Anderson Cancer Center | Cytokine-treated Veto Cells CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel | IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2 | Phase 1 | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal Cancer | Dec 2027 |
| Pop Test Oncology | Org-34517 (PT150) Glucocorticoid receptor antagonist | NR3C1 | Phase 1 | Alcohol Use Disorder | Jul 2028 |
| University of California, Davis | Desonide Glucocorticoid receptor agonist | NR3C1 | Phase 1 | Healthy | – |
| University Hospital, Lille | TRIXEO AEROSPHERE (BGF 160) Fixed triple combination: long-acting beta-2 agonist (formoterol), long-acting muscarinic | ADRB2, CHRM3, NR3C1 | Phase 1 | Copd | – |
Asthma (8) Oral Lichen Planus (4) Breast Cancer (4) Chronic Obstructive Pulmonary Disease (3) Nicotine Dependence (3) Frozen Shoulder (2) IgA Nephropathy (2) Prostate Cancer (2) Hand Osteoarthritis (2) Cataract (2) Psoriasis Vulgaris (2) Cytomegalovirus (CMV) (2)
small molecule (48), mixed (4), other (1)
Corcept Therapeutics (4) Memorial Sloan Kettering Cancer Center (3) M.D. Anderson Cancer Center (2) Diakonhjemmet Hospital (1) University of Palermo (1) McMaster University (1) Christiaan Vinkers (1) Oticara Australia (1) Montefiore Medical Center (1) Universitas Padjadjaran (1) University of Alabama at Birmingham (1) AstraZeneca (1) University of Chicago (1) Daniel Raper, MBBS (1) Leiden University Medical Center (1) Venkatesh Sampath (1) Sint Maartenskliniek (1) Eupraxia Pharmaceuticals (1) Chelsea and Westminster NHS Foundation Trust (1) Wake Forest University Health Sciences (1)
PGR (6) ADRB2 (3) IL12B (2) IL23A (2) HTR2A (2) CHRM3 (2) TGFBR2 (2) AGTR1 (1) PDCD1 (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.